Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1)

Vaccine

Volumn 27, Issue 52, 2009, Pages 7451-7458

  Yang, Shi gui ^a,b   Wo, Jian er ^a   Li, Min wei ^a   Mi, Fen fang ^c   Yu, Cheng bo ^a   Lv, Guo liang ^a   Cao, Hong Cui ^a   Lu, Hai feng ^a   Wang, Bao hong ^a   Zhu, Hanping ^b   Li, Lan Juan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Influenza A (H5N1) virus; Replicons; Vaccine; VP22

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; INTERLEUKIN 4; PROTEIN VP22; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS VACCINE; VP22 HEMAGGLUTININ FUSION PROTEIN;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON;

ALPHAVIRUS; ANIMALS; BIRDS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; PHYLOGENY; PLASMIDS; REPLICON; VIRAL STRUCTURAL PROTEINS;

EID: 70549100122     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.014     Document Type: Article

References (48)

1. Osterhaus A.D. Pre- or post-pandemic influenza vaccine?. Vaccine 25 27 (2007) 4983-4984
2. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 5349 (1998) 393-396
3. de Jong J.C., Claas E.C.J., Osterhaus A.D.M.E., Webster R.G., and Lim W.L. A pandemic warning?. Nature 389 6651 (1997) 554
4. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO; 2009. http://www.who.int/csr/disease/avian influenza/country/cases_table2009.02.09/en/index.html [accessed 9 February 2009].
5. Murakami S., Iwasa A., Iwatsuki-Horimoto K., Ito M., Kiso M., Kida H., et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26 50 (2008) 6398-6404
6. Saha S., Yoshida S., Ohba K., Matsui K., Matsuda T., Takeshita F., et al. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 354 1 (2006) 48-57
7. Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H., et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 80 10 (1999) 2559-2564
8. Lo C.-Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.-P., et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26 17 (2008) 2062-2072
9. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J Infect Dis 148 5 (1983) 775-784
10. Shi H., Liu X.F., Zhang X., Chen S., Sun L., and Lu J. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. Vaccine 25 42 (2007) 7379-7384
11. Francis T., Salk J.E., and Quilligan J.J. Experience with vaccination against influenza in the Spring of 1947: a preliminary report. Am J Public Health Nations Health 37 8 (1947) 1013-1016
12. Kodihalli S., Kobasa D.L., and Webster R.G. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 18 23 (2000) 2592-2599
13. Neumann G., Castrucci M.R., and Kawaoka Y. Nuclear import and export of influenza virus nucleoprotein. J Virol 71 12 (1997) 9690-9700
14. Wang S., Zhang C., Zhang L., Li J., Huang Z., and Shan L. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26 17 (2008) 2100-2110
15. Whittaker G., Bui M., and Helenius A. Nuclear trafficking of influenza virus ribonuleoproteins in heterokaryons. J Virol 70 5 (1996) 2743-2756
16. Leitner W.W., Bergmann-Leitner E.S., Hwang L.N., and Restifo N.P. Type I interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 24 24 (2006) 5110-5118
17. Escriou N, van der Werf S, Vignuzzi M, Gerbaud S. Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins. US Patent WO 02/095023, PCT/IB02/02810; 2001.
18. Rayner J.O., Dryga S.A., and Kamrud K.I. Alphavirus vectors and vaccination. Rev Med Virol 12 5 (2002) 279-296
19. Greer C.E., Zhou F., Legg H.S., Tang Z., Perri S., Sloan B.A., et al. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25 3 (2007) 481-489
20. Li N., Qiu H.-J., Zhao J.-J., Li Y., Wang M.-J., Lu B.-W., et al. A Semliki Forest virus replicon vectored DNA vaccine expressing the E2 glycoprotein of classical swine fever virus protects pigs from lethal challenge. Vaccine 25 15 (2007) 2907-2912
21. Hung C.F., Cheng W.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166 9 (2001) 5733-5740
22. Kim T.W., Hung C.F., Kim J.W., Juang J., Chen P., He L.M., et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 15 2 (2004) 167-177
23. Parida R., Shaila M.S., Mukherjee S., Chandra N.R., and Nayak R. Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential. Vaccine 25 43 (2007) 7530-7539
24. Influenza virus resource; 2009. http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html [accessed 9 February 2009].
25. Polo J.M., Belli B.A., Driver D.A., Frolov I., Sherrill S., Hariharan M.J., et al. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci USA 96 8 (1999) 4598-4603
26. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., et al. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77 19 (2003) 10394-10403
27. Wu T.C., Guarnieri F.G., Staveley-O'Carroll K.F., Viscidi R.P., Levitsky H.I., Hedrick L., et al. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci USA 92 25 (1995) 11671-11675
28. Subbarao K., Murphy B.R., and Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 24 1 (2006) 5-9
29. Stephenson I., Nicholson K.G., Wood J.M., Zambon M.C., and Katz J.M. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4 8 (2004) 499-509
30. Veits J., Römer-Oberdörfer A., Helferich D., Durban M., Suezer Y., Sutter G., et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26 13 (2008) 1688-1696
31. Shortridge K.F., Zhou N.N., Guan Y., Gao P., Ito T., Kawaoka Y., et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252 2 (1998) 331-342
32. Nicholson K.G., Wood J.M., and Zambon M. Influenza. Lancet 362 9397 (2003) 1733-1745
33. Webby R.J., Perez D.R., Coleman J.S., Guan Y., Knight J.H., Govorkova E.A., et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363 9415 (2004) 1099-1103
34. Nichols W.W., Ledwith B.J., and Manam S.V. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 772 27 (1995) 30-39
35. Booy R., Brown L.E., Grohmann G.S., and Macintyre C.R. Pandemic vaccines: promises and pitfalls. Med J Aust 185 10 (2006) S62-65
36. Thomas P.G., Keating R., Hulse-Post D.J., and Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 12 1 (2006) 48-54
37. Rimmelzwaan G.F., Fouchier R.A., and Osterhaus A.D. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18 6 (2007) 529-536
38. + T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 26 52 (2008) 6965-6974
39. Thompson J.M., Whitmore A.C., Staats H.F., and Johnston R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26 39 (2008) 4998-5003
40. Hubby B., Talarico T., Maughan M., Reap E.A., Berglund P., Kamrud K.I., et al. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25 48 (2007) 8180-8189
41. Ying H., Zaks T.Z., Wang R.F., Irvine K.R., Kammula U.S., Marincola F.M., et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 5 7 (1999) 823-827
42. Saxena S., Dahiya S.S., Sonwane A.A., Patel C.L., Saini M., Rai A., et al. A Sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine 26 51 (2008) 6592-6601
43. Schlesinger S., and Dubensky T.W. Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol 10 5 (1999) 434-439
44. Frolov I., and Schlesinger S. Comparison of the effects of Sindbis virus and Sindbis virus replicons on host cell protein synthesis and cytopathogenicity in BHK cells. J Virol 68 3 (1994) 1721-1727
45. Perkins S.D., Hartley M.G., Lukaszewski R.A., Phillpotts R.J., Stevenson F.K., and Bennett A.M. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine 23 16 (2005) 1931-1940
46. Gillim-Ross L., and Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 19 4 (2006) 614-636
47. Luke C.J., and Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 12 1 (2006) 66-72
48. Suguitan Jr. A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 9 (2006) e360